Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.87 USD

28.87
12,948,956

-0.22 (-0.76%)

Updated Sep 30, 2024 03:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab

by Zacks Equity Research

Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.

The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

by Zacks Equity Research

Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Kinjel Shah headshot

Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates

by Kinjel Shah

Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.

Pfizer (PFE) RSV Vaccine Found Effective in Older Adults

by Zacks Equity Research

Based on the positive data from the phase III study on its RSV vaccine candidate, Pfizer plans to file a biologics license application (BLA) to the FDA in fall 2022.

Akero Therapeutics (AKRO) Up on Positive NASH Study Data

by Zacks Equity Research

Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.

Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.

Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.

Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada

by Zacks Equity Research

Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.

Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RDIV

Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents

by Zacks Equity Research

Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.

Sanofi (SNY) Ends Development of Breast Cancer Drug, Stock Down

by Zacks Equity Research

Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.

Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose

by Zacks Equity Research

Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.

Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails

by Zacks Equity Research

Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.

Should First Trust Rising Dividend Achievers ETF (RDVY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for RDVY

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

by Zacks Equity Research

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023

by Kinjel Shah

Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.

    Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

    by Zacks Equity Research

    Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

    Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth

    by Zacks Equity Research

    Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.

    Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half

    by Zacks Equity Research

    Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.

    Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings

    by Zacks Equity Research

    Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.

    Biohaven Pharmaceutical (BHVN) Q2 Earnings Lag, Sales Beat

    by Zacks Equity Research

    Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. BHVN also reports a wider-than-expected Q2 loss.